Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events

Giuseppe Murdaca, Barbara Maria Colombo, Francesco Puppo

Research output: Contribution to journalArticle

Abstract

B-cells abnormalities leading to autoantibody production play a central role in Systemic Lupus Erythematosus (SLE) pathogenesis. B-cell targeted therapies, including anti-B lymphocyte stimulator (BLyS) and anti-CD20 monoclonal antibodies, are at forefront of new SLE treatments. Biologic agents targeting specific pathways (i.e. T-B lymphocyte interaction, cytokines and complement) have been also proposed as new tools for SLE treatment. In this review we will focus on biological drugs whose potential efficacy has been evaluated in open-label and randomized clinical trials.

Original languageEnglish
Pages (from-to)56-60
Number of pages5
JournalAutoimmunity Reviews
Volume11
Issue number1
DOIs
Publication statusPublished - Nov 2011

Keywords

  • B cells
  • Biological therapies
  • Cytokines
  • Systemic Lupus Erythematosus

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events'. Together they form a unique fingerprint.

  • Cite this